Abstract Number: 1310 • 2012 ACR/ARHP Annual Meeting
Analysis of Anti-JC Polyomavirus T-Cell Immune Response with JC-Feron in Patients with Rheumatoid Arthritis Treated with Rituximab or Anti-TNF
Background/Purpose: Some cases of progressive multifocal leukoencephalopathy (PML) have been described in patients with autoimmune diseases with profound immunosuppression, due to replication of JC polyomavirus…Abstract Number: 1311 • 2012 ACR/ARHP Annual Meeting
A Novel Individualized Treatment Approach in Open-Label Extension Study of Ozoralizumab (ATN-103) in Subjects with Rheumatoid Arthritis On a Background of Methotrexate
Background/Purpose: Ozoralizumab (ATN-103), a novel TNFα inhibitor, is a trivalent, bispecific Nanobody® that potently neutralises TNF and binds to human serum albumin to increase its…Abstract Number: 1312 • 2012 ACR/ARHP Annual Meeting
Clinical Response At 12 Weeks Predicts Long-Term Remission and the Extent of Radiographic Progression in Japanese Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol with and without Methotrexate Coadministration
Background/Purpose: The majority of patients (pts) with active rheumatoid arthritis (RA) have previously been shown to respond during the first 12 weeks (wks) of certolizumab…Abstract Number: 1313 • 2012 ACR/ARHP Annual Meeting
Tolerance of Rituximab in Patients with a History of Cancer : Data From the Registry Air
Background/Purpose: Data regarding tolerance of biologics in patients with a history of cancer are very limited. We therefore analyzed tolerance of rituximab (RTX) in patients…Abstract Number: 1314 • 2012 ACR/ARHP Annual Meeting
Validation of Algorithms Using Genome-Wide SNP Analysis for Prediction of Remission or Low Disease Activity for Infliximab or Etanercept-Treated RA Patients
Background/Purpose: Achievement of remission or low disease activity with infliximab (IFX) and etanercept (ETN) treatment is currently one of the most important matters in RA…Abstract Number: 1315 • 2012 ACR/ARHP Annual Meeting
Gene Expression Profiling and Pathway Changes Associated with Clinical Response to Tabalumab Blockade of Membrane Bound and Soluble B Cell Activating Factor in Rheumatoid Arthritis
Background/Purpose: Tabalumab, a monoclonal antibody neutralizing membrane bound and soluble B cell activating Factor (BAFF), has been shown to reduce the signs and symptoms of…Abstract Number: 1276 • 2012 ACR/ARHP Annual Meeting
Changes in B Cell Populations and Serum Immunoglobulins and Their Relationship to Infections in a One Year, Uncontrolled Open Label Study of Tabalumab
Background/Purpose: B cell activating factor (BAFF) is an important modulator of B cell development and proliferation and is secreted by neutrophils, monocytes, macrophages and dendritic…Abstract Number: 1277 • 2012 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: Year 2 Efficacy and Safety Results From a 24-Month Phase 3 Study
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This 24‑month (Mo) Phase 3…Abstract Number: 1278 • 2012 ACR/ARHP Annual Meeting
Tuberculosis and Tofacitinib Therapy in Patients with Rheumatoid Arthritis
Background/Purpose: Biologic therapies that block tumor necrosis factor-alpha (TNF) increase the risk of tuberculosis (TB), and screening for latent tuberculosis infection (LTBI) before their initiation…Abstract Number: 1279 • 2012 ACR/ARHP Annual Meeting
First in Human Study with Recombinant Anti-IL-21 Monoclonal Antibody in Healthy Subjects and Patients with Rheumatoid Arthritis
Background/Purpose: Interleukin-21 (IL-21), a cytokine produced by activated T cells (especially T17 and TFH cells), has a proinflammatory and pleiotropic nature, and drives mainly activation…Abstract Number: 1280 • 2012 ACR/ARHP Annual Meeting
Sustained Efficacy Responses and a Consistent Safety Profile with Rituximab Repeat Treatment Over 5 Years in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumour Necrosis Factor Inhibitors
Background/Purpose: In the REFLEX study conducted in anti-TNF inadequate responder (TNF-IR) patients with RA, a single course of rituximab (RTX) in combination with methotrexate (MTX)…Abstract Number: 1281 • 2012 ACR/ARHP Annual Meeting
IL-6 Signaling Inhibition Improves Abnormal Bone Homeostasis in Active Rheumatoid Arthritis
Background/Purpose: Tocilizumab (TCZ) is a humanized monoclonal anti-IL-6 receptor antibody. TCZ has demonstrated efficacy in moderate to severe active rheumatoid arthritis (RA) with inadequate clinical…Abstract Number: 1282 • 2012 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy up to 48 Months
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy in RA. Here we report the safety…Abstract Number: 1283 • 2012 ACR/ARHP Annual Meeting
Effects of Tofacitinib On Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis Receiving Stable-Dose Methotrexate: Results of Two Phase 3 Studies
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. The efficacy and safety of…Abstract Number: 1284 • 2012 ACR/ARHP Annual Meeting
Evaluation of Influenza and Pneumococcal Vaccine Responses in Patients with Rheumatoid Arthritis Receiving Tofacitinib
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. Clinical guidelines recommend the use…